Opacification of the urinary tract in portal venous spiral CT without delayed scans

In portal venous spiral CT there is no visible renal contrast excretion within the usual period of scanning. To opacify collecting systems additional delayed scanning is required. We administered an extra pre-dose of contrast medium before the main portal venous bolus in order to opacify the urinary tract and studied its effects on liver attenuation. In 32 patients examined first by non-contrast spiral CT 20 ml of a non-ionic IV CM were injected. Five minutes later, orientating cuts in the liver and along the urinary tract were obtained. Immediately thereafter, a 120-ml bolus was administered at 3 ml/s for portal venous phase helical CT (60-s delay craniocaudad). The quality of renal excretion was graded visually (excellent, fair, poor, none). Hepatic attenuation measurements were performed at comparable regions of interest. In all patients 20 ml CM opacified the renal pelvis after 5 min. Depiction of the ureters was excellent in 14, fair in 11 and poor or none in 7 cases. There was little effect on mean hepatic attenuation by the 20-ml pre-bolus after 5 min: mean enhancement 2.3 HU (range –0.6 to 7.8 HU). Mean hepatic enhancement after the 120-ml portal venous bolus ranged between 23.6 and 74.1 HU (mean 51.5 HU). When opacification of the urinary tract is necessary, pre-administration of a 20-ml bolus 5 min before portal venous scanning may save an extra delayed spiral. The effects on hepatic enhancement are negligible. Received: 29 October 1998; Revision received: 6 January 1999; Accepted: 1 February 1999     

Enhancement of the liver on dynamic MDCT: investigation among three groups consisting of noncirrhotic patients and cirrhotic patients with and without a large portosystemic shunt

Purpose The aim of this study was to determine any difference in hepatic enhancement values on dynamic multidetector row computed tomagraphy (MDCT) among three groups: noncirrhotic patients and cirrhotic patients with and without a large portosystemic shunt. Materials and methods A group of 20 noncirrhotic patients (group A), 43 cirrhotic patients without a large shunt (group B), and 20 cirrhotic patients with a large shunt (group C) underwent dynamic MDCT of the liver using a standard concentration (300 mg I/ml) and volume (100 ml) of contrast material. The attenuation values of the liver were measured during arterial, portal, and late phases. Results The hepatic enhancement value during the portal phase was significantly higher in group A (56.2 ± 13.7 HU) than in the other two groups (group B 39.8 ± 11.9 HU, group C 41.3 ± 8.3 HU) (P < 0.01). No significant difference was present between group B and group C. The regression line of the scattergram, which shows the relation between the hepatic enhancement value during the portal phase and the iodine dose per the patients' body weight was more gently sloping in group C than in the other two groups. Conclusion In cirrhotic patients without a large shunt, injection of a larger amount of total iodine is necessary to optimize hypovascular tumor visualization. However, in cirrhotic patients with a large shunt, further investigation is needed concerning the effectiveness of administering a larger amount of total iodine.     

Quantitative prediction of contrast enhancement from test bolus data in cardiac MSCT

The purpose of this study was to evaluate a new algorithm for the prediction of contrast enhancement from test bolus data in cardiac multislice spiral computed tomography (MSCT). An algorithm for the prediction of contrast enhancement using test bolus data was developed. A total of 30 consecutive patients (15 male, 69.5 ± 9.6 years) underwent cardiac MSCT (12 × 0.75 mm, 120 kV, 500 mAs_eff.) with a biphasic contrast material injection protocol. Contrast timing was derived from a standard 20 ml test bolus injection. Based on the test bolus time attenuation curves, expected enhancement values were computed for the ascending and descending aorta and the pulmonary trunk and compared with measured data from the cardiac CT scan. At the level of the test bolus measurement in the ascending aorta, the corresponding attenuation values were 309.4 ± 49.6 Hounsfield Units (HU) for the predicted and 285.6 ± 42.6 HU for the measured attenuation, respectively. The mean deviation between predicted and measured CT values was 32.8 ± 48.2 HU (upper and lower limits of agreement 101.4/−53.8 HU), indicating a slight systematic tendency for overestimation. For 80% of the patients the prediction error was less than 50 HU. Prediction of contrast enhancement in cardiac MSCT from test bolus data is feasible with a relatively small mean deviation; 80% of the predictions were within a range that might be acceptable for routine clinical application.     

Automatic bolus tracking in monophasic spiral CT of the liver: liver-to-lesion conspicuity

The aim of this study was to evaluate the value of automatic bolus tracking for monophasic spiral CT of the liver and to assess the liver-to-lesion conspicuity in comparison with time-delay examinations. In 40 patients scheduled for therapy control of known hypovascular hepatic metastases a monophasic spiral CT was completed either with time delay of 65 s (n = 20) or with automatic bolus tracking in the liver parenchyma (n = 20). Examinations were performed with 120 ml of contrast material and a flow rate of 3.0 ml/s. For automatic bolus tracking a parenchymal enhancement threshold of 40 HU was used. Contrast enhancement in the liver parenchyma and in liver lesions was obtained by means of regions of interest (ROI). Mean parenchymal enhancement was not significantly different between time delay and bolus-tracking group. In 4 of 20 patients in the bolus-tracking group the threshold level of 40 HU was not reached. With automatic bolus tracking a significantly higher liver-to-lesion density difference was observed (P < 0.0001). Automatic bolus tracking allows a better liver-to-lesion conspicuity in monophasic spiral CT. Contrary to recent studies, a significantly higher parenchymal enhancement was not found using automatic bolus tracking. Received: 13 July 2000 Accepted: 19 July 2000     

螺旋CT门静脉造影延迟时间的合理选择

应用时间－密度曲线选择螺旋ＣＴ门静脉造影的合理扫描延迟时间。材料与方法１４例正常人和１２例重度肝硬化患者于第一门水平行同层动态增扫描。造影剂量为２ｍｌ／ｋｇ体重,注射速率３ｍｌ／ｓ。经外周静脉注射造影剂后１５ｓ开始扫描,以后每隔５ｓ扫描１次,持续至１２０ｓ。分别测同一层面门静脉,肝脏,脾脏的ＣＴ值,并计算各时间各时点民肝脏的密度差,描绘时间－密度曲线,结果正常组与肝硬化组门静脉平均强化峰值和达到时     

Clinical evaluation of a computer simulated prediction model of contrast enhancement of the liver in spiral CT

OBJECTIVE: A software program was developed simulating a compartmental model of blood circulation based on differential equations. The aim of this study was to compare software-simulated levels of hepatic enhancement with the true values in patients and to test how many patients reach the simulated hepatic enhancement level. METHODS: As software program the CT application software carebolus 2 (Siemens, Forchheim, Germany) was used. Hepatic contrast-enhancement curves were simulated prior to CT examinations to evaluate a patient specific time delay after contrast application. At the time delay, when the simulation curve showed an enhancement threshold of 40 Hounsfield Units (HU), the CT spiral scan was started applying 120 ml contrast media with 2 ml/s. The simulated curves were compared with the empiric curves of each patient. RESULTS: 25 of 28 patients (89%) achieved 40 HU. The mean enhancement of empiric patients curves was 46.32 +/- 11.9 HU, the mean simulated enhancement was 46.62 +/- 4.3 HU S.D. (P= 0.48). 4.4 values per patient liver could be compared with the simulation curve (122 points for 28 patients): 50% of the patient curves were within a range of 5 HU compared with the simulation curve. CONCLUSION: Software simulation of contrast enhancement curves of the liver is a feasible and valuable method to predict individual liver enhancement curves. Improvements concerning the integration of cardiovascular parameters and preexisting liver parenchymal diseases into the simulation software have to be arranged.     

Multiphase contrast-enhanced CT of the liver with a multislice CT scanner

Our objective was to assess the effects of the injection rate of contrast material and of a 5% dextrose flush on enhancement in multiphase hepatic CT using a multislice CT scanner. Most patients had chronic hepatitis and/or liver cirrhosis. One hundred eighty examinations, in which two sequential acquisitions were performed during a single breath-hold followed by third- and fourth-pass acquisitions, were randomized into four protocols: contrast injection at 0.1 ml/kg body weight s^–1 over 21 s without and with a 30-ml flush in groups 1 and 2, respectively, and contrast injection at 0.07 ml/kg body weight s^–1 over 30 s without and with a flush in groups 3 and 4, respectively. Contrast enhancement in each acquisition was measured in the aorta, portal vein, and liver. The visualization of hepatic arterial branches was scored by visual assessment. The highest aortic enhancement was observed in the first-pass acquisition in all groups. At the higher injection rate (groups 1 and 2), aortic enhancement in the first-pass acquisition was significantly more intense, whereas portal venous and hepatic enhancement was significantly less intense. The use of a flush considerably improved aortic enhancement at the beginning of the second-pass acquisition. In the visual assessment of hepatic arterial branches, the protocols with the higher injection rate received significantly higher grades. Multislice CT permits the entire liver to be imaged during an almost exclusively arterial phase by shortening the injection duration for a given volume of contrast material. Electronic Publication     

Late-arterial and portal-venous phase imaging of the liver with a multislice CT scanner in patients without circulatory disturbances: automatic bolus tracking or empirical scan delay?

The value of automatic bolus tracking in late-arterial and portal-venous phase imaging of the liver with a multislice CT scanner as compared with fixed time-delay examination in patients without circulatory disturbances is evaluated. For the evaluation of known or suspected liver disease, 98 multiphase contrast-enhanced CT examinations including double late-arterial phase imaging were randomized into either scanning with a scan delay of 30 s from the beginning of contrast material injection or scanning with automatic bolus tracking. Contrast material was injected at 0.07 ml/kg body weight/s over 30 s. Contrast enhancement in each acquisition was measured in the aorta, portal vein, liver, pancreas and hepatocellular carcinomas. The density difference between hepatocellular carcinomas and the hepatic parenchyma was calculated. The mean time to the first-pass acquisition as determined by automatic bolus tracking was 29.6 s. No statistically significant difference was observed between the two groups either in any enhancement in any acquisition or in the lesion-to-liver density difference. The use of automatic bolus tracking in late-arterial and portal-venous phase hepatic CT does not significantly improve the degree of contrast enhancement in the aorta, portal vein, liver and pancreas or lesion-to-liver conspicuity in patients without circulatory disturbances.     

Improvement of parenchymal and vascular enhancement using saline flush and power injection for multiple-detector-row abdominal CT

The aim of this study was to determine if a saline solution flush following low dose contrast material bolus improves parenchymal and vascular enhancement during abdominal multiple detector-row computed tomography (MDCT). Forty-one patients (24 men and 17 women; mean age 49 years, age range 27–86 years) underwent abdominal MDCT (collimation 4×5 mm, 15-mm table increment, reconstruction interval 5 mm, gantry rotation period 0.8 s) with a single- as well as with a double syringe power injector. Indication for examination were benign and malignant tumors and inflammatory diseases. Patients received 100 ml nonionic contrast material (300 mgI/ml) alone or pushed with 20 ml saline solution. Mean enhancement values for both protocols were measured in the liver, the spleen, the pancreas, the renal cortex, the portal vein, the inferior vena cava and the abdominal aorta. Double syringe power-injector protocol led to significantly higher parenchymal and vascular enhancement than single syringe power-injector protocol (p<0.05). The improvement in mean enhancement of the liver was 9±9 HU, of the spleen 8±10 HU, of the pancreas 7±9 HU, and of the renal cortex 8±20 HU. The improvement in mean enhancement of the portal vein was 10±17 HU of the inferior vena cava 8±13 HU and of the abdominal aorta 10±17 HU. The use of a double syringe power injector with saline flush following contrast material bolus significantly improves parenchymal and vascular enhancement during contrast-enhanced abdominal MDCT with low iodine doses.     

MR imaging of the liver: Effect of portal hypertension on hepatic parenchymal enhancement using a gadolinium chelate

The purpose of this study was to prospectively investigate the extent to which reduced portal blood flow in patients with hepatic cirrhosis and portal hypertension affects hepatic parenchymal enhancement during gadolinium-chelate-enhanced dynamic MR imaging. Breath-hold three-dimensional (3D) spoiled gradientrecalled echo (GRE) MR imaging technique obtained after intravenous administration of a gadolinium chelate was used to measure hepatic parenchymal enhancement and time to peak enhancement in 20 patients with hepatic cirrhosis and clinical evidence of portal hypertension (group 1) and in 20 control subjects without portal hypertension (group 2) who were matched for age, sex, and body weight. Mean peak hepatic enhancement values ± SD and times to peak enhancement ± SD were determined for both groups of patients. Mean peak enhancement value (±SD) was 78.7% ± 36.2 in group 1 and 91.6% ± 46.2 in group 2 (not significant). However, in the nine patients in group 1 with splenomegaly, mean peak enhancement value was 61.3% ± 14.4, whereas it was 93.0% ± 42.7 in the 11 patients without splenomegaly (P < .05). Mean time to peak enhancement was 84 seconds ± 23 in group 1 and 54.0 sec ± 25.0 in group 2 (P < .01). Our results show that mean peak enhancement value of hepatic parenchyma after intravenous administration of a gadolinium chelate is significantly altered for patients with portal hypertension and splenomegaly. In addition, the time to peak enhancement is delayed significantly when portal hypertension is present. Thus, it is possible that the optimal time for imaging the liver during the portal phase must be tailored to the status of the portal system of the patient.     

Biphasic spiral CT of the liver: automatic bolus tracking or time delay?

The aim of this study was to evaluate the value of automatic bolus tracking for biphasic spiral CT of the liver in comparison with time delay examinations. Forty patients scheduled for a biphasic spiral CT of the liver randomly were examined either with time delay of 25 s for the arterial phase and 55 s for the portal-venous phase (n = 20), or with an automatic scan start triggered by contrast enhancement in the aorta (n = 20). Examinations were performed with 120 ml of contrast material and a flow rate of 4.0 ml/s. Density measurements of the aorta, of the liver parenchyma, and of the spleen were obtained by means of regions of interest (ROI). The end of the arterial phase was considered when hepatic parenchymal enhancement was greater than 20 HU. In all patients of the group with automatic bolus tracking arterial scanning was completed in the arterial phase of the liver. In 25 % of patients with fixed time delay, however, an enhancement of liver parenchyma during arterial phase greater than 20 HU was observed. During the portal-venous phase there was no significant difference in parenchymal enhancement between both groups. Automatic bolus tracking allows an individualized timing of the arterial phase in biphasic spiral CT of the liver. The timing is more accurate than in time delay scanning. Received: 18 February 2000 Revised: 13 July 2000 Accepted: 19 July 2000     

[F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland

Objective  We determined the glucose metabolism and computed tomographic (CT) density of the normal prostate gland in relation to age and prostate size on [F-18] fluorodeoxyglucose positron emission tomography (PET)-CT. Methods  We determined the CT density (Hounsfield Units, HU) and glucose metabolism (standardized uptake value, SUV) of the normal prostate in 145 men (age range 22–97 years) on PET-CT scans which were performed for indications unrelated to prostate pathology. Correlations among SUV, HU, prostate size, and age were calculated using Pearson’s correlation coefficients, scatter plots, and linear regression trend lines. The SUV and HU values were also compared among different primary cancer types using the Kruskal-Wallis test. Results  The population average and range of the normal prostate size were 4.3 ± 0.5 cm (mean ± SD) and 2.9–5.5 cm, respectively. The population average of mean and maximum CT densities was 36.0 ± 5.1 HU (range 23-57) and 91.7 ± 20.1 HU (range 62-211), respectively. The population average of mean and maximum SUV was 1.3 ± 0.4 (range 0.1–2.7) and 1.6 ± 0.4 (range 1.1–3.7), respectively. Mean SUV tended to decrease as the prostate size increased (r = −0.16, P = 0.058). Higher mean HU was correlated with higher mean SUV (r = 0.18, P = 0.033). The strongest association was observed between age and prostate size. The prostate gets larger as age increases (r = 0.32, P < 0.001). Prostate mean SUV, max SUV, mean HU, and max HU were not significantly different among different types of primary cancers. Conclusions  Although the normal prostate size increases with age, it does not significantly affect the gland’s metabolism and CT density, and therefore age-correction of these parameters may be unnecessary.     

Optimal dose and injection duration (injection rate) of contrast material for depiction of hypervascular hepatocellular carcinomas by multidetector CT

Purpose The aim of this study was to investigate the optimal dose and injection duration of contrast material (CM) for depicting hypervascular hepatocellular carcinomas (HCCs) during the hepatic arterial phase with multidetector row computed tomography (CT). Materials and methods The study population consisted of 71 patients with hypervascular HCCs. After unenhanced scans, the first (early arterial phase, or EAP), second (late arterial phase, or LAP), and third (equilibrium phase) scanning was started at 30, 43, and 180 s after injection of contrast material (CM). During a 33-s period, patients with a body weight ≤50 kg received 100 ml of non-ionic CM with an iodine concentration of 300 mg I/ml; patients whose body weight was >50 kg received 100 ml of CM with an iodine concentration of 370 mg I/ml. First, we measured enhancement in the abdominal aorta and tumor-to-liver contrast (TLC) during the EAP and LAP. Next, to investigate the relation between aortic enhancement and TLC during the LAP, two radiologists visually assessed the conspicuity of hypervascular HCCs during the LAP using a 3-point scale: grade 1, poor; grade 2, fair; grade 3, excellent. Finally, to examine the effect of the CM dose and injection duration on aortic enhancement during the EAP, we simulated aortic enhancement curves using test bolus data obtained for 10 HCC patients and the method of Fleischmann and Hittmair. Results A relatively strong correlation was observed between aortic enhancement during the EAP and TLC during the LAP (correlation coefficient r = 0.75, P < 0.001). The 95% confidence intervals for the population mean for aortic enhancement during EAP in patients with tumor conspicuity grades of 1, 2, and 3 were 188.5, 222.4; 228.8, 259.3; and 280.2, 322.5 HU (Hounsfield Unit), respectively. Thus, we considered the lower limit of the aortic enhancement value for excellent depiction of HCCs during EAP to be 280 HU. To achieve an aortic enhancement value of >280 HU for aortic enhancement simulations during EAP, the injection duration should be <25 s for patients receiving a CM dose of 1.7 ml/kg with 300 mg I/ml iodine and <30 s for those receiving 2.0 ml/kg. Conclusions For excellent depiction of hypervascular HCCs during the hepatic arterial phase, the injection duration should be <25 s in patients receiving a CM dose of 1.7 ml/kg with 300 mg I/ml iodine and <30 s for patients receiving 2.0 ml/kg.     

身体指数与主动脉和肝脏CT强化程度的相关性研究

目的探讨上腹部CT增强扫描时,身高(HT)、全体重(TBW)、体重指数(BMI)、去脂肪体重(LBW)、体表面积(BSA)和血容量(BV)与主动脉和肝脏强化程度的相关性。方法回顾性分析2014年7月至8月广东省人民医院行肝脏CT多期增强扫描的113例患者,测量上述身体指数和肝动脉期主动脉、门静脉期肝脏的强化值(ΔHU)。将主动脉和肝脏ΔHU值根据患者的性别、TBW和BMI各分成亚组,分别是男性组和女性组,TBW<60 kg组和TBW≥60 kg组,BMI<25 kg/m^2组和BMI≥25 kg/m^2组,采用t检验比较不同亚组患者主动脉、肝脏ΔHU值的差异。各身体指数与每克碘主动脉、肝实质增强值(ΔHU/gI)的相关性采用线性回归分析。结果男性患者肝动脉期主动脉的ΔHU、门静脉期肝实质的ΔHU均低于女性患者,差异均有统计学意义(P<0.05)。TBW<60 kg患者的主动脉和肝脏的ΔHU值均高于TBW≥60 kg患者,差异有统计学意义(P<0.05);BMI<25 kg/m^2和BMI≥25 kg/m^2患者的肝脏ΔHU差异有统计学意义,BMI<25 kg/m^2患者高于BMI≥25 kg/m^2患者(P<0.05)。15例患者肝脏ΔHU低于50 HU,男性比例(18.3%,11/60)高于女性(7.5%,4/53)。肝动脉期主动脉ΔHU/gI值与LBW的负相关程度最明显(r=-0.559,P<0.01),门静脉期肝脏ΔHU/gI值与BSA的负相关程度最明显(r=-0.680,P<0.01)。结论主动脉、肝脏CT增强扫描时,可采用LBW或BSA代替TBW作为个性化计算碘对比剂用量的身体指数。     

Usefulness of saline pushing in reduction of contrast material dose in abdominal CT: evaluation of time-density curve for the aorta, portal vein and liver

The effects of saline pushing after contrast material injection were investigated as well as the possibility for this technique to reduce contrast material doses in liver CT examinations. 52 patients were divided randomly into three groups: 100 ml of contrast material (300 mg I ml(-1)) only (A; n = 19), 100 ml of contrast material pushed with 50 ml of saline solution (B; n = 17), and 85 ml of contrast material pushed with 50 ml of saline solution (C; n = 16). Single-level images were obtained at the level of the main portal vein after the initiation of contrast material injection. There were no significant differences in the mean peak enhancement values (PE) and the mean time to peak enhancement values (TPE) of the aorta between the three groups. The mean PE of the portal vein in group B increased 21 HU over that in group A (p<0.05), and there was no significant difference between groups A and C. The mean PE of the liver in group B increased 7 HU over that in group A (p<0.05), and there was no significant difference between groups A and C. The mean TPE of the portal vein was shorter by 4 s (p<0.05), and that of the liver was shorter by 5 s (p<0.05) in group C compared with those in group A. In conclusion, saline pushing increases the enhancement values of the portal vein and liver, and allows a contrast material dose reduction of 15 ml without decreasing hepatic and vascular enhancement at adequate scan timing.     

Optimization of automatic bolus tracking for timing of the arterial phase of helical liver CT

The aim of this study was to optimize bolus tracking for timing of the arterial phase of biphasic helical liver CT and to compare optimized bolus tracking to a standard delay. One hundred fifty patients were examined with six protocols: 5- or 10-s delay after triggering at a threshold of 50 or 75 or 100 HU enhancement in the aorta at the origin of the celiac arteries after injection of 120 ml contrast material at 3 ml/s. Optimal arterial enhancement was defined as 20-30% of hepatic enhancement in portal venous phase. Another 50 patients were examined with the optimized protocol and compared to 50 gender- and age-matched patients who underwent a 25-s standard delay. A 10-s delay after the 75-HU threshold resulted in the most patients with an optimal arterial phase (p < 0.01). Thirty-one of 75 patients examined with this protocol showed optimal early liver enhancement. Bolus tracking compared with standard delay revealed only a trend for a difference (p = 0.07). The outcome of automatic bolus tracking differs depending on the protocol used; however, optimal arterial phase imaging was seen in only 41% of patients, indicating only a trend for superior timing compared with a standard delay.     

Helical CT of the liver with computer-assisted bolus-tracking technology: scan delay of arterial phase scanning and effect of flow rates

PURPOSE: The purpose of this work was to assess the scan delay and the effect of flow rates on arterial phase scanning of hepatic CT. METHOD: One hundred twenty patients suspected of having hepatocellular carcinoma were examined by three-phase helical CT using computer-assisted bolus-tracking technology. We set the region of interest (ROI) in the abdominal aorta at the level of the celiac artery as a baseline. The triggering threshold was set at 100 HU. A volume of 100 ml of iomeprol (350 mg of I/ml) was administered at 2, 2.5, or 3 ml/s i.v. RESULTS: In all cases, helical CT scanning began after reaching the ROI threshold. Then, portal venous phase scanning was initiated 50 s after arterial phase initiation. The mean delay time from the initiation of contrast agent administration to the beginning of arterial phase scanning was 29.2 +/- 3.8 s (mean +/- SD, range 22-39 s). A faster injection rate significantly shortened the scan delay (p < 0.01). In portal venous phase scanning, calculated areas under the hepatic enhancement curves were almost equal among different injection rates. CONCLUSION: The computer-assisted bolus-tracking technology is a useful method for determining an individual scan delay of arterial phase CT.     

Novel connecting tube for saline chaser in contrast-enhanced CT: the effect of spiral flow of saline on contrast enhancement

Objective

To evaluate the effect of a newly developed connecting tube, which generates a spiral flow of saline, on aortic and hepatic contrast enhancement during hepatic-arterial phase (HAP) and portal venous phase (PVP) computed tomography (CT).

Methods

Eighty patients were randomly assigned to one of two protocols: with a new or a conventional tube. The contrast material (600 mgI/kg) was delivered over 30 s; this was followed by the administration of 25 ml saline solution delivered at the same injection rate as the contrast material. Unenhanced and contrast-enhanced CT images of the upper abdomen were obtained. We calculated the changes in the CT number (?HU) for the aorta during HAP and PVP, and for the liver during PVP. We compared ?HU between protocols.

Results

The mean ?HU for the abdominal aorta during HAP was significantly higher with the new tube protocol than with the conventional tube protocol (322?±?53 vs. 290?±?53, P?<?0.01). There were no significant differences in the mean ?HU for the abdominal aorta and liver during PVP between the two protocols (P?>?0.05).

Conclusion

The new connecting tube increased the effect of a saline chaser and significantly improved aortic enhancement during HAP.

Key Points

? Optimal administration of intravenous contrast material is essential for optimal CT quality. ? A new connecting tube can generate spiral flow, which improves intravenous administration. ? The new connecting tube improved aortic contrast enhancement during the hepatic-arterial phase. ? The new connecting tube increased the effect of a saline chaser.     

Preoperative portal vein embolization using an amplatzer vascular plug

The purpose was to evaluate the safety and efficacy of preoperative portal vein embolization (PVE) using an Amplatzer vascular plug (AVP). Forty-one patients who underwent PVE using gelatin sponge particles and the AVP were enrolled. The right portal branches were embolized using gelatin sponges (1–8 mm³) through a 5-F catheter, and the AVP was deployed at the first- or second-order right portal vein. Technical success and complications, recanalization, and changes of total estimated liver volumes (TELV), future liver remnant (FLR), and FLR/TELV were evaluated. Follow-up CT performed 6–43 days (median, 16 days) after PVE was used to evaluate volume parameters. PVE was technically successful in 40 of 41 patients. Major complications occurred in two patients, with one each having extensive portal vein thrombosis and liver abscess. Partial recanalization of the occluded portal vein was seen in one patient. The mean FLR volume (653 ± 174 ml vs. 532 ± 154 ml, p < 0.001) and mean FLR/TELV ratio (43 ± 8% vs 36 ± 7%, p < 0.001) were significantly higher after than before PVE. PVE using the AVP seems to be a relatively safe and effective technique for inducing hypertrophy of the FLR with minimal risk of recanalization.     

Weight-adapted iodinated contrast media administration in abdomino-pelvic CT: Can image quality be maintained?

IntroductionIn many centres, a fixed method of contrast-media administration is used for CT regardless of patient body habitus. The aim of this trial was to assess contrast enhancement of the aorta, portal vein, liver and spleen during abdomino-pelvic CT imaging using a weight-adapted contrast media protocol compared to the current fixed dose method.MethodsThirty-nine oncology patients, who had previously undergone CT abdomino-pelvic imaging at the institution using a fixed contrast media dose, were prospectively imaged using a weight-adapted contrast media dose (1.4 ml/kg). The two sets of images were assessed for contrast enhancement levels (HU) at locations in the liver, aorta, portal vein and spleen during portal-venous enhancement phase. The t-test was used to compare the difference in results using a non-inferiority margin of 10 HU.ResultsWhen the contrast dose was tailored to patient weight, contrast enhancement levels were shown to be non-inferior to the fixed dose method (liver p < 0.001; portal vein p = 0.003; aorta p = 0.001; spleen p = 0.001). As a group, patients received a total contrast dose reduction of 165 ml using the weight-adapted method compared to the fixed dose method, with a mean cost per patient of £6.81 and £7.19 respectively.ConclusionUsing a weight-adapted method of contrast media administration was shown to be non-inferior to a fixed dose method of contrast media administration. Patients weighing 76 kg, or less, received a lower contrast dose which may have associated cost savings. A weight-adapted contrast media protocol should be implemented for portal-venous phase abdomino-pelvic CT for oncology patients with adequate renal function (>70 ml/min/1.73 m²).